Expert Perspectives on VVC Introduction July 14, 2020 1 - - PowerPoint PPT Presentation

▶
expert perspectives on vvc
SMART_READER_LITE
LIVE PREVIEW

Expert Perspectives on VVC Introduction July 14, 2020 1 - - PowerPoint PPT Presentation

Jan 25, 2023 285 likes •945 views

Expert Perspectives on VVC Introduction July 14, 2020 1 Ibrexafungerp ( ibrexa or IBX) is an investigational drug. Forward-Looking Statements Certain statements regarding SCYNEXIS, Inc. (the Company) made in this presentation

slide-1
SLIDE 1

1

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Expert Perspectives on VVC

July 14, 2020

Introduction

slide-2
SLIDE 2

2

Forward-Looking Statements

Certain statements regarding SCYNEXIS, Inc. (the “Company”) made in this presentation constitute forward-looking statements, including, but not limited to, statements regarding our business strategies and goals, plans and prospects, market size, adoption rate, potential revenue, clinical validity and utility, growth opportunities, future products and product pipeline. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. These risks and uncertainties include, but are not limited, to: risks inherent in SCYNEXIS's ability to successfully develop and obtain FDA approval for ibrexafungerp; the expected costs of studies and when they might begin or be concluded; whether the positive results from the FURI trial to date will continue to be achieved as the study continues; uncertainties about the regulatory standards for approval through LPAD; and SCYNEXIS's reliance on third parties to conduct SCYNEXIS's clinical studies. Forward-looking statements may be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “could,” “should,” “would,” “may,” “will,” “believes,” “estimates,” “potential,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward- looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent reports filed with the Securities and Exchange Commission ("SEC"), including under the caption “Risk Factors” in the Company’s annual report on Form 10-K for the year ended December 31, 2019 and in the Company’s subsequent quarterly reports on Form 10-Q, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking

  • statements. The Company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances

after the date of this presentation, or to reflect actual outcomes.

slide-3
SLIDE 3

3

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Agenda

Introduction

  • Dr. Marco

Taglietti CEO 10:00

VVC Disease State

KOLs: Barbara Dehn, NP &

  • Dr. Caroline

Mitchell 10:10

Ibrexa Overview & Progress

  • Dr. Nkechi Azie

VP of Clinical Development & Medical Affairs 10:45

VVC Market Opportunity

Jim Maffezzoli VP of Marketing & Sales 11:00

Q&A Session

Open to all 11:15

Closing Remarks

  • Dr. Marco

Taglietti CEO 11:45

slide-4
SLIDE 4

4

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Innovation Creates Value

Value for Public Health Agencies Who seek to promote innovative anti-infective agents to guard against future pathogens

Value for VVC patients

With limited treatment options and poor quality of life who want to feel “normal”

Value for Health Care Providers

Who need an alternative mode-of-action therapy and seek to reduce frustration of patients and improve their satisfaction

Value for Savvy Investors & Loyal Shareholders

Who recognize true innovation

Value for Strategic Partners

To complement existing portfolios in underserved disease areas

slide-5
SLIDE 5

5

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Ibrexafungerp: Most Clinically Advanced Innovation in Antifungals

A new antifungal, in a novel class Innovation in Drug Development Innovation in Women’s Health Innovation in Hospital Setting

  • Potential to introduce

the FIRST new antifungal class in

  • ver 20 years…
  • … and more than 40

years after the introduction of oral azoles

  • Potential to be the

first new oral, non- azole, product for treatment of VVC

  • In development for

prevention of recurrent VVC for which nothing is approved

  • Active against

multidrug-resistant fungi, including emerging Candida auris

slide-6
SLIDE 6

scynexis.com

The Im Impact of VVC

Barbara Dehn NP

slide-7
SLIDE 7

Nurse Practit itio ioners 290,000 NPs in US 75% provide Primary Care Over 1 billion patient visits/year

slide-8
SLIDE 8

Examine, Dia iagnose, Prescribe

Private practices Urgent Care Walk in Clinics Reproductive Centers Planned Parenthood Emergency Rooms Hospitals

slide-9
SLIDE 9
slide-10
SLIDE 10

Usual Pathway to Relief

  • 1. Hope it goes away
  • 2. Online research
  • 3. OTC remedy
  • 4. “Natural” remedies
  • 5. Hope it goes away
  • 6. Office visit
slide-11
SLIDE 11

Under appreciated Not well understood Under reported

Shrouded in Shame

slide-12
SLIDE 12

12

Vulvovaginal Candidiasis, VVC:

A fungal infection of the lower female reproductive tract

slide-13
SLIDE 13

Afflicts 75% of women at least once in their lifetime

Yearly

9 million women in the US 138 million women worldwide 50% of women will have a recurrence 8% will have 3+ episodes in a year = recurrent rVVC Not Associated with STI’s

VVC

slide-14
SLIDE 14

Treatments: Oft ften repeated 1 cla class: AZOLEs

  • Over the Counter Creams
  • Clotrimazole
  • Miconazole
  • Tioconazole
  • Oral medication
  • Fluconazole
  • Prescription Intravaginal Creams
  • Butoconazole
  • Terconazole
  • Other agents
  • Boric Acid
  • Nystatin
slide-15
SLIDE 15

VVC Risk Factors

Prior use of Antibiotics Diabetes Obesity Use of Corticosteroids Pregnancy Immunocompromised

slide-16
SLIDE 16

Recurrent VVC

  • 3-4 times/year
  • Pain with sex
  • Inflammation and Rash
  • Cracks, fissures in skin

Impacts

  • Work
  • Self esteem
  • Relationship
  • Energy level
  • Physical functioning
slide-17
SLIDE 17

Why doesn’t this go away? Why are you giving me the same thing….Again?

slide-18
SLIDE 18

Vulvovaginal candidiasis

Caroline Mitchell, MD, MPH Associate Professor, Obstetrics & Gynecology Massachusetts General Hospital & Harvard Medical School

slide-19
SLIDE 19

Who am I?

slide-20
SLIDE 20

Why should you care about VVC?

slide-21
SLIDE 21

Vulvovaginal candidiasis is common

75%

slide-22
SLIDE 22

Current treatments

Topical Oral

Miconazole Terconazole Clotrimazole Tioconazole Butaconazole Fluconazole (Itraconazole) (Voriconazole)

slide-23
SLIDE 23

Why does the field need a new medication?

Zhou Mycoses 2016 (PMID 27073145); Sobel AJOG 2001; Nyirjesy JL LGTD 2019; Li Med Mycol 2015

SS < 2 SS = 0 Mycologic 20 40 60 80 100 Percent cured

Cure at 1 month ranges from 50-80%, depending on the definition of “cure”

slide-24
SLIDE 24

Many medical conditions have multiple types of treatment

  • ptions

1 3 5 11 VVC Blood thinners Diabetes (oral) High blood pressure

slide-25
SLIDE 25

Current azole therapies have limitations

Pro Con Topical azoles Easy Irritating Messy Fluconazole Easy Can’t use in pregnancy Incomplete efficacy Medication interactions Itraconazole, Voriconazole Familiar Not in guidelines Potential liver toxicity Less efficacy

slide-26
SLIDE 26

OTC and alternative

  • ptions
slide-27
SLIDE 27

OTC and alternative

  • ptions
slide-28
SLIDE 28

Probiotics are ineffective to prevent recurrence

Czaja Pirotta Witt Kovachev 10 20 30 40 50

% with recurrent VVC

Probiotic Placebo

Adapted from van de Wijgert BJOG 2019

slide-29
SLIDE 29

The other

  • ptions have

significant limitations

Flucytosine & Amphotericin

$18-30 $1400

slide-30
SLIDE 30

Special cases

 Pregnancy  Recurrence  Fluconazole-resistant C. albicans  Non-albicans species

Kennedy Curr Infect Dis Rep; Ameen Jl Mycol Med 2017; Goncalves Crit Rev Microbiol

slide-31
SLIDE 31

Special cases

 Pregnancy  Recurrence  Fluconazole-resistant C. albicans  Non-albicans species

Candida species % cases (US) % cases (world)

  • C. albicans

70-89% 35-90%

  • C. glabrata

3-15% 3-50%

  • C. tropicalis

1% 0.2 – 18%

  • C. parapsilosis

4-8.9% 0.5 - 10%

  • C. kruseii

0.1% 0.1 – 6%

Kennedy Curr Infect Dis Rep; Ameen Jl Mycol Med 2017; Goncalves Crit Rev Microbiol

slide-32
SLIDE 32

Fluconazole is contraindicated in pregnancy

 Denmark  1.4 million pregnancies  Increased risk for miscarriage

32

1 2 Hazard Ratio

Molgaard-Nielsen JAMA 2016

Risk of miscarriage between 7-23 weeks

Fluconazole

slide-33
SLIDE 33

Recurrent VVC

 Between 5-9% of women have rVVC at any one time  After 6 months weekly fluconazole suppression , 50-60% of women have a recurrence  Among 191 women with rVVC, the median duration of fluconazole suppressive therapy was 16 months during 3 years of follow-up  By age 50, 25% of women in the US report experiencing rVVC (lasting 1-4 years)

Goncalves Crit Rev Microbiol 2017; Denning Lancet ID 2018; Collins Jl LGTD 2020; Sobel AJOG 2016

slide-34
SLIDE 34

Fluconazole- resistance

  • r

Non-albicans

 Boric acid  Higher-dose Fluconazole  Itraconazole or Ketoconazole  Topical azole  Vaginal nystatin  Vaginal Gentian violet  Compounded vaginal flucytosine 17%/Amphotericin B 3%

Sobel & Sobel Expert Opinion Pharmacotherapy 2018

slide-35
SLIDE 35

A patient story

slide-36
SLIDE 36

36

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

First Representative of a Novel Oral Antifungal for the Treatment of VVC

Ibrexafungerp Overview

Nkechi Azie, MD, MBA, FIDSA

Pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections

slide-37
SLIDE 37

37

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Nkechi Azie, MD, MBA, FIDSA

  • Dr. Azie has over 25 years of experience in the areas of Infectious

Diseases, Women’s Health, CNS, Immunology and Gastro-Intestinal Disease.

  • Previous experience:

– Medicines Company – Senior Vice President Medical Affairs – Astellas – Senior Medical Director Clinical Development and Medical Affairs – Pfizer – Medical Director Clinical Development – Pharmacia- Associate Medical Director – Eli Lily – Research Fellow – Indiana University Medical Center – Infectious disease specialist Physician

  • Dr. Azie received an executive MBA from the University of Notre

Dame and a Medical degree from the University of Nigeria.

  • Dr Azie is board certified in Infectious Disease and Clinical

Pharmacology.

Vice President Clinical Development and Medical Affairs

slide-38
SLIDE 38

38

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Ibrexafungerp for VVC

No Safety Signals Phase 3 Program Successfully Completed Broad- spectrum of Activity Different From the Start Kills Candida

slide-39
SLIDE 39

39

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal

  • Similar MoA target to Echinocandins - Glucan Synthase Inhibitor
  • Echinocandins gold standard for treatment of hospital-based Candida infections

Ibrexafungerp: First Oral Glucan Synthase Inhibitor Glucan Synthase Inhibitor Echinocandins (e.g., Caspofungin)

CASPOFUGIN

Structurally distinct: Allowing oral delivery

IBREXAFUNGERP

Available only in Intravenous Formulation, not available orally

slide-40
SLIDE 40

40

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Validated MoA Differentiated binding vs. echinocandins

Fungal Cell

Nucleus Cell Wall β-(1,6)-glutan Mannoproteins Chitin Phospholipid bilayer

  • f cell membrane

Ergosterol

(Polyenes site
  • f interaction)

Ergosterol Synthesis Pathway

(Azoles site of interaction)

β-(1,3)-glucan synthase

(SCY-078 and echinocandins site of interaction)

Depletion of β-(1,3)-glucans in cell wall

  • C. auris before SCY-078
  • C. auris after SCY-078

Larkin E., et al. The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation. Antimicrob Agents Chemother. 2017 May; 61(5)

Ibrexafungerp MoA: Glucan Synthase Inhibitor

Cell Membrane and Cell Wall

β-(1,3)-glucan

slide-41
SLIDE 41

41

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Different From the Start-

The First Non-azole Treatment for VVC

Novel Class Triterpenoid Active Against Azole-resistant Candida No Cross Resistance with Azoles Exclusive Fungal Target Fungicidal Against Candida Proven Gold Standard MoA vs. Candida All prescription VVC drugs are Azoles

slide-42
SLIDE 42

42

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Gets To and Potent at Disease Site

In Vitro Activity is Not Impaired at Vaginal pH Take With Or Without Food Plasma to Genital Tissue Ratio: Ibrexafungerp –1: 9 Fluconazole – 1: 0.7 - 1.0

Oral 1-Day Treatment 20-hour Half-Life

slide-43
SLIDE 43

43

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Ibrexafungerp Safety and Tolerability

Pre-clinical

No end organ toxicity No fetal toxicity

Clinical

Well Tolerated > 1200 dosed Majority of AEs were GI-related: mild and transient

No Hepatotoxicity No Renal Toxicity No QTC effect Minimal DDIs

slide-44
SLIDE 44

44

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Ibrexafungerp Path Forward for VVC

  • Two Phase 3 acute VVC studies successfully completed → superiority vs. placebo
  • U.S. study (VANISH 303): positive top-line data released in Nov. 2019
  • Global study (VANISH 306): positive top-line data released in Apr. 2020
  • Program consistent with EMA scientific advice
  • One global Phase 3 recurrent VVC study (~350 patients; superiority vs. placebo)
  • ngoing
  • SPA agreement with FDA received in July 2019

Key Milestones

DOVE P2b

(Jul 2018) 1 P3 (VANISH-303) Complete

1 P3 (CANDLE) – SPA agreement Ongoing

NDA H2:20 sNDA H2:21 1 P3 (VANISH-306) Complete Positive Data Nov 2019 Positive Data Apr 20‘20 Potential Approval Mid-2021

2018 2019 2020 2021

Treatment of VVC (VANISH) Prevention of Recurrent VVC (CANDLE)

slide-45
SLIDE 45

45

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

VANISH Phase 3 Program – Ibrexafungerp Efficacy

Efficacy at Day-10 TOC and Day-25 FU (mITT) Ibrexafungerp VVC Phase 3 Program VANISH-306

IBX 300mg BID (n=188)

VANISH-303

IBX 300mg BID (n=188)

Clinical Cure (0 S&S) at TOC 63.3%* 50.5%** Mycological Eradication at TOC 58.5%** 49.5%** Clinical Improvement (0 or 1 S&S) at TOC 72.3%* 64.4%** Complete Symptom Resolution at FU 73.9%** 59.6%*

* p value ≤ 0.01 ** p value ≤ 0.001

Ibrexafungerp met its endpoints and achieved highly statistically significant superiority vs. placebo in two well-controlled studies

slide-46
SLIDE 46

46

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Ibrexafungerp in VVC Clinical Studies: Sustained Efficacy at Follow-up Visit (Day 25)

  • Consistent efficacy of ibrexafungerp across studies
  • Sustained efficacy with higher clinical cure rates at Day 25

63% 74% 51% 60% 52% 70% 58% 50%

0% 20% 40% 60% 80% TOC (Day-10) FU (Day-25) TOC (Day-10) FU (Day-25) TOC (Day-10) FU (Day-25) TOC (Day-10) FU (Day-25)

Fluconazole

Clinical Cure (0 S&S)

VANISH-306 IBX 300mg BID (n=188)

DOVE Phase 2 Study VANISH Phase 3 Studies

VANISH-303 IBX 300mg BID (n=188) DOVE P2 Study IBX 300mg BID (n=27) DOVE P2 Study FLU 150mg (n=24)

slide-47
SLIDE 47

47

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Ibrexafungerp – Safety Consistent with Prior Findings

  • Combined safety database of VANISH and DOVE

programs includes more than 850 patients enrolled, with 575 ibrexafungerp-treated patients (one-day 300mg BID dose)

  • No systemic safety issues | No discontinuations due

to study drug

  • The majority of Treatment-Emergent AEs (TEAEs)
  • bserved at a higher frequency in the ibrexafungerp

group were gastrointestinal in nature

  • The three most common GI events were

diarrhea/loose stool, nausea, abdominal pain

Safety Set VANISH + DOVE IBX 300mg BID (n=575) Diarrhea/ Loose Stool 16.7%

76% mild

Nausea 11.8%

87% mild

Abdominal Pain 4.5%

92% mild

slide-48
SLIDE 48

48

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Ibrexafungerp: a Novel Fungicidal Oral Agent for the Treatment of VVC

Ibrexafungerp Fluconazole

Mechanism of Action beta-(1,3)-D-glucan synthase inhibitor 14α-demethylase inhibitor Cidal/Static vs. Candida Fungicidal Fungistatic Active vs. azole-resistant Candida Yes No Activity Impacted at low vaginal pH Yes No Vaginal tissue/Plasma ratio 9:1 1:1 Evidence of Fetal Toxicity (pre- clinical) No Yes Evidence of QTC prolongation No Yes Evidence of Liver Toxicity No Yes One-day Oral dose Yes Yes

The Vaginal Yeast Infection market only has treatments from one class (azoles) and no treatment options with a different MoA

slide-49
SLIDE 49

49

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

July 14, 2020

Jim Maffezzoli

Ibrexafungerp Commercial Opportunity

slide-50
SLIDE 50

50

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Jim Maffezzoli

  • Mr. Maffezzoli has over 25 years of experience in

marketing and commercialization, most recently as the Senior Vice President of Marketing at women’s health company Viveve Medical.

  • Prior to Viveve, Mr. Maffezzoli held several commercial

leadership roles in Urology and Women’s Health at Allergan plc, Exeltis USA, Inc. (a division of the global pharmaceutical group Insud Pharma) and Pfizer Inc.

  • Prior to Pfizer Mr. Maffezzoli held several marketing

and P&L leadership roles for Nabisco and Kraft Inc.

  • Mr. Maffezzoli holds an M.B.A. from the J.L. Kellogg

Graduate School of Management at Northwestern University, and a B.A. in Political Economy from Princeton University.

Vice President of Marketing and Sales

slide-51
SLIDE 51

51

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

VVC Is a Multi-Billion Dollar Opportunity

US Market Opportunity Overview

Ibrexafungerp Peak U.S. Net Sales Potential $400 - $600M

(does not include conversion of any of the 18M annual OTC units) Total Rx/year (14.2M Oral Flu + 1.2M Topical) Assumed WAC Price Value of Total Addressable Market (in billions)

15.4M $300 - $400 $5.6 - $6.2

✓ Large oral market (5-yr CAGR: 3%) ✓ Only one-class of products (azoles) ✓ No new product in over 25 years ✓ No Branded Product ✓ No Promotion in over 15 years

92% 8%

Oral Topical

Majority of women prefer an Oral Rx treatment vs a Rx cream

slide-52
SLIDE 52

52

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Integrated Multi-stakeholder Launch Optimization Framework Aligns Access and Demand Strategies

Market Stakeholders Launch Framework Brand Objectives

Access

Payer

Access

Provider

Availability

Demand

Prescriber

Adoption

Patient

Acquisition & Adherence Launch Strategy Adoption Propensity Analysis

Value Realization

slide-53
SLIDE 53

53

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Prescribers Are Excited about Ibrexafungerp

  • Ibrexafungerp’s main benefits are seen to be:

✓ Convenient dosing (Oral) ✓ First-in-Class MoA (fungicidal vs. fungistatic) ✓ Broad-spectrum activity (including resistance) ✓ No safety signals

  • HCPs expect to use Ibrexafungerp for treatment

mainly for 2nd or 3rd or subsequent episodes of VVC

✓ Several HCPs also want to try it on a proportion of 1st episode patients particularly those who have comorbidities

Really like it – after 20 years finally something new I’d use it for all my patients No safety signals or DDIs concerns It’s fungicidal

slide-54
SLIDE 54

54

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

HCPs See Strong Potential for Ibrexafungerp Across All Patient Segments

29% 48% 59% 59% First Episode Third Episode 4+ Episode 8.3M Second Episode 4.5M 1.7M 900K Unadjusted Preference Shares

“Recurrent”

Total VVC Rx/year 15.4M

Treatment

slide-55
SLIDE 55

55

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Engaging Payers Early to Maximize Ibrexafungerp’s Potential

Putting strategies in place minimizes insurance restrictions

✓ Develop key access strategies

  • Value Proposition
  • Analytics and segmentation
  • Pricing, Contracting, Distribution
  • Co-pay management

✓ Hire highly experienced “A plus” level Account Directors to deliver value message to payers ✓ Pre-approval Information Exchange and Awareness Build

  • Educate on disease burden, unmet need, and current treatments including

the limitations of fluconazole

  • Educate on the clinical and economic value of Ibrexa
  • Introduce SCYNEXIS

Key Initiatives:

slide-56
SLIDE 56

56

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Robust Segmentation and Targeting Will Enable Lean and Flexible Demand Generation

  • More effective than deciles
  • Predictive Formulary Access & HCP

Adoption

– Network algorithms and machine learning (50 variables, 2,900 products) – Multilevel regression analysis and health system overlay

  • Non-launch target digital efforts to

generate and nurture leads

  • Target list updated as coverage and

HCP adoption changes

Increased productivity and uptake

Propensity to Prescribe Access Favorability

Launch Customers

slide-57
SLIDE 57

57

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Women Are a Key Customer

  • Under-Appreciated

– Pain, disruption, and impact on QoL are generally not acknowledged

  • Under-Reported

– Many are ashamed, see it as something to live with and blame themselves

  • Not Well-Served

– Confusion, fear, limited education – Limited Effective Treatments

84% 16%

HCP would prescribe if patient requested HCP would not prescribe if patient requested

HCP Willingness to Grant an Ibrexafungerp Request

slide-58
SLIDE 58

58

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

SCYNEXIS’ Approach to Patients Designed to Increase Marketing Effectiveness and Efficiency

  • Digital Landscape - Sizing
  • Customer Language Analysis
  • Database of Intentions
  • Digital Buying Process
  • HCP Social Influencers Mapping
  • Digital Landscape Segmentation
  • Competitive Content Mapping
  • Content Gap Analysis
  • 360 Patient Journey

Superior Insights

Better Informed and Relevant Content and Placement Strategies More Targeted and Effective Infrastructure

slide-59
SLIDE 59

59

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Yeast Infection Digital Landscape – Evidence of Considerable Market Opportunity

Yeast Infection Menopause Breast Cancer Ovarian Cancer Menstrual Cramps Urinary Incontinence

1.1M

363K 343K8 238K 174K 46K

Yeast Infection

A lead topic in women’s health search velocity Digital is their source for information and conversation High educational need Search analysis shows the market to be larger than expected

Top Search Questions Monthly Volume

slide-60
SLIDE 60

60

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Yeast Infection Digital Landscape – Evidence of Considerable Market Opportunity

6MM+

total searches per month

45k+

specific questions covered

40+

causes / risk factors asked about

30+

potential treatments explored

…but few medication brand options

A lead topic in women’s health search velocity Digital is their source for information and conversation High educational need Search analysis shows the market to be larger than expected

slide-61
SLIDE 61

61

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Information Action Evaluation Next Step

Problem Identification

  • What causes YI?
  • Why do I keep getting YI?

Solution Exploration

  • How to get rid of a YI?
  • What is the best YI treatment?

Solution Evaluation

  • What are fluconazole's side

effects?

  • What are Monistat's reviews?

Solution Decision

  • Where to buy Monistat?
  • Can you buy fluconazole OTC?

Solution Execution

  • How to use Monistat?
  • When to take second fluconazole?

Solution Effect Monitoring

  • How long does it take for

fluconazole to work?

  • Does Monistat burn?

Solution Modification

  • Fluconazole not working what

to do?

  • Why does Monistat increase

itching?

Episode Conclusion & Forward Management

  • What to eat to prevent YI?
  • How to prevent recurring YI?

Multiple Opportunities along the Buying Decision Process for SCYNEXIS Impact

slide-62
SLIDE 62

62

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Targeting for Efficient AND High-Impact Digital Marketing

Highest Priority High Priority

Total Market

100% of total searches

True Market – Core

Complicated Cases … Rx

True Market – Relevant

OTC / Other Medications

Where To Compete

slide-63
SLIDE 63

63

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Highest Priority High Priority

Total Market

100% of total searches

Targeting for Efficient AND High-Impact Digital Marketing

True Market – Core

Complicated Cases … Rx

True Market – Relevant

OTC / Other Medications

Where To Compete What To Say

Queries & Competitive Review Content Unmet Needs (Gaps) Content Roadmap

slide-64
SLIDE 64

64

Ibrexafungerp (”ibrexa” or ”IBX”) is an investigational drug.

Commercial Summary

VVC is a large underserved market that has not seen either a new product in over 25 years or promotion in over 15 years Ibrexafungerp has a well-liked product profile that prescribers want to use across a broad range of patients SCYNEXIS’ multi-stakeholder integrated launch strategies provide a path to cost effective launch that will maximize the value of Ibrexafungerp in VVC

slide-65
SLIDE 65

scynexis.com

Thank You